cd19-targeted non-viral pd1 site-specific integrated car-t cell injection
Cell therapyexperimental
Clinical trial activity
1 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Mar 30, 2023 (NCT05741359)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- B-lymphocyte antigen CD19Immunity, passive
CD19 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05741359 | Phase 1 | Mar 30, 2023 | Chinese Academy of Medical Sciences, Huazhong University of Science and Technology, Shanghai Bioray Laboratory Inc., Zhejiang University |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Huazhong University of Science and Technology | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Shanghai Bioray Laboratory Inc. | For profit | 1 | 1 | 1 | 2023 |
| Zhejiang University | Academic/Hospital | 1 | 0 | 1 | 2023 |
4 organizations
Page 1 / 1